LOGIN
No difference in darexaban taken qd or bid at 30 or 60 mg total in preventing VTE post-THA
June 2014
No difference in darexaban taken qd or bid at 30 or 60 mg total in preventing VTE post-THA
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3)
Thromb Haemost. 2014 Jan 29;111(2):213-25. doi: 10.1160/TH13-04-0296.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
1992 patients undergoing elective total hip arthroplasty were randomized to receive either oral darexaban (YM150) (at 15 mg bid, 30 mg qd, 30 mg bid, or 60 mg qd) or 40 mg enoxaparin qd. Incidence of VTEs or death was the primary outcome, and incidence of bleeding and adverse events were part of the safety analysis. No significant differences were found between bid and qd darexaban dosing, as well...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.